Evaluation of Parameters Affecting the Occurrence of Systemic Inflammatory Response Syndrome in Patients Operated on Due to Kidney Tumors
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Group and Design
2.2. Statistical Methods
3. Results
3.1. Study Group Characteristics
3.2. SIRS Occurrence on the First Day after Surgery Due to a Kidney Tumor
3.3. Factors Influencing SIRS Occurrence on the First Day after Surgery Due to a Kidney Tumor
3.4. SIRS Occurrence on the Third Day after Surgery Due to a Kidney Tumor
3.5. Factors Influencing SIRS Occurrence on the Third Day after Surgery Due to a Kidney Tumor
3.6. Complications Occurrence after Surgery Due to a Kidney Tumor
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed]
- Choueiri, T.K.; Je, Y.; Cho, E. Analgesic use and the risk of kidney cancer: A meta-analysis of epidemiologic studies. Int. J. Cancer 2014, 134, 384–396. [Google Scholar] [CrossRef] [PubMed]
- Franklin, J.R.; Figlin, R.; Belldegrun, A. Renal cell carcinoma: Basic biology and clinical behavior. Semin. Urol. Oncol. 1996, 14, 208–215. [Google Scholar]
- Talmor, M.; Hydo, L.; Barie, P.S. Relationship of systemic inflammatory response syndrome to organ dysfunction, length of stay, and mortality in critical surgical illness: Effect of intensive care unit resuscitation. Arch. Surg. 1999, 134, 81–87. [Google Scholar] [CrossRef] [PubMed]
- Stephenson, J.A.; Gravante, G.; Butler, N.A.; Sorge, R.; Sayers, R.D.; Bown, M.J. The systemic inflammatory response syndrome (SIRS)—Number and type of positive criteria predict interventions and outcomes in acute surgical admissions. World J. Surg. 2010, 34, 2757–2764. [Google Scholar] [CrossRef]
- NeSmith, E.G.; Weinrich, S.P.; Andrews, J.O.; Medeiros, R.S.; Hawkins, M.L.; Weinrich, M. Systemic inflammatory response syndrome score and race as predictors of length of stay in the intensive care unit. Am. J. Crit. Care 2009, 18, 339–346. [Google Scholar] [CrossRef]
- Comstedt, P.; Storgaard, M.; Lassen, A.T. The systemic inflammatory response syndrome (SIRS) in acutely hospitalised medical patients: A cohort study. Scand. J. Trauma Resusc. Emerg. Med. 2009, 17, 67. [Google Scholar] [CrossRef]
- Bochicchio, G.V.; Napolitano, L.M.; Joshi, M.; Knorr, K.; Tracy, J.K.; Ilahi, O.; Scalea, T.M. Persistent systemic inflammatory response syndrome is predictive of nosocomial infection in trauma. J. Trauma 2002, 53, 245–251. [Google Scholar] [CrossRef]
- Hadasik, G.; Hadasik, K.; Święszek, A. Usefulness of testing for the prevalence of systemic inflammatory response syndrome (SIRS) in clinical practice. Chir. Pol. 2014, 16, 12–19. [Google Scholar]
- Karpel, E. Zespół Ogólnoustrojowej Reakcji Zapalnej w Okresie Pooperacyjnym. Habilitation Thesis, Medical University of Silesia, Katowice, Poland, 2001. (In Polish). [Google Scholar]
- Albers, P.; Heidenreich, A.; Lech, H. Podstawowe Operacje Urologiczne; Czelej: Lublin, Poland, 2007. (In Polish) [Google Scholar]
- Smith, J.A.; Howards, S.S.; Preminger, G.M.; Dmochowski, R.R. Hinman’s Atlas of Urologic Surgery; Elsevier/Saunders: Philadelphia, PA, USA, 2012. [Google Scholar]
- Lau, W.K.; Blute, M.L.; Weaver, A.L.; Torres, V.E.; Zincke, H. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin. Proc. 2000, 75, 1236–1242. [Google Scholar] [CrossRef]
- Lerner, S.E.; Hawkins, C.A.; Blute, M.L.; Grabner, A.; Wollan, P.C.; Eickholt, J.T.; Zincke, H. Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J. Urol. 2002, 167, 884–889. [Google Scholar] [CrossRef]
- Weir, C.B.; Jan, A. BMI Classification Percentile and Cut Off Points; StatPearls Publishing: Treasure Island, FL, USA, 2021. [Google Scholar]
- Quesenberry, C.P., Jr.; Caan, B.; Jacobsen, A. Obesity, health service use, and health care costs among members of a health maintenance organization. Arch. Int. Med. 1998, 158, 466–472. [Google Scholar] [CrossRef]
- Cave, M.C.; Hurt, R.T.; Frazier, T.H.; Matheson, P.J.; Garrison, R.N.; McClain, C.J.; McClave, S.A. Obesity, inflammation, and the potential application of pharmaconutrition. Nutr. Clin. Pract. 2008, 23, 16–34. [Google Scholar] [CrossRef]
- Chen, Z.; Wittenberg, S.; Auer, T.A.; Bashkuev, M.; Gebert, P.; Fehrenbach, U.; Geisel, D.; Graef, F.; Maerdian, S.; Tsitsilonis, S. The effect of fat distribution on the inflammatory response of multiple trauma patients—A retrospective study. Life 2021, 11, 1243. [Google Scholar] [CrossRef]
- Southern, J.B.; Higgins, A.M.; Young, A.J.; Kost, K.A.; Schreiter, B.R.; Clifton, M.; Fulmer, B.R.; Garg, T. Risk factors for postoperative fever and systemic inflammatory response syndrome after ureteroscopy for stone disease. J. Endourol. 2019, 33, 516–522. [Google Scholar] [CrossRef]
- Gu, W.; Zhu, Y.; Wang, H.; Zhang, H.; Shi, G.; Liu, X.; Ye, D. Prognostic value of components of body composition in patients treated with targeted therapy for advanced renal cell carcinoma: A retrospective case series. PLoS ONE 2015, 10, e0118022. [Google Scholar] [CrossRef]
- Ladoire, S.; Bonnetain, F.; Gauthier, M.; Zanetta, S.; Petit, J.M.; Guiu, S.; Kermarrec, I.; Mourey, E.; Michel, F.; Krause, D.; et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist 2011, 16, 71–81. [Google Scholar] [CrossRef]
- Steffens, S.; Grunwald, V.; Ringe, K.I.; Seidel, C.; Eggers, H.; Schrader, M.; Wacker, F.; Kuczyk, M.A.; Schrader, A.J. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor–targeted therapy? Oncologist 2011, 16, 1565–1571. [Google Scholar] [CrossRef]
- Mano, R.; Hakimi, A.A.; Zabor, E.C.; Bury, M.A.; Donati, O.F.; Karlo, C.A.; Bazzi, W.M.; Furberg, H.; Russo, P. Association between visceral and subcutaneous adiposity and clinicopathological outcomes in non-metastatic clear cell renal cell carcinoma. Can. Urol. Assoc. J. 2014, 8, E675–E680. [Google Scholar] [CrossRef]
- Hakimi, A.A.; Furberg, H.; Zabor, E.C.; Jacobsen, A.; Schultz, N.; Ciriello, G.; Mikklineni, N.; Fiegoli, B.; Kim, P.H.; Voss, M.H.; et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. JNCI J. Nat. Cancer Inst. 2013, 105, 1862–1870. [Google Scholar] [CrossRef]
- Dai, J.; Zhang, X.; Liu, Z.; Song, T.; Zhu, X.; Zhang, H.; Wu, M.; Li, X.; Zeng, H.; Shen, P. The prognostic value of body fat components in metastasis renal cell carcinoma patients treated with TKIs. Cancer Manag. Res. 2020, 12, 891–903. [Google Scholar] [CrossRef] [PubMed]
- Yang, X.-F.; Ma, G.; Feng, N.-H.; Yu, D.-S.; Wu, Y.; Li, C. Twist2 and CD24 expression alters renal microenvironment in obesity associated kidney cancer. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 358–364. [Google Scholar]
- Waalkes, S.; Merseburger, A.S.; Kramer, M.W.; Herrmann, T.R.; Wegener, G.; Rustemeier, J.; Hofmann, R.; Schrader, M.; Kuczyk, M.A.; Schrader, A.J. Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. Cancer Causes Control 2010, 21, 1905–1910. [Google Scholar] [CrossRef] [PubMed]
- Rogde, A.J.; Gudbrandsdottir, G.; Hjelle, K.M.; Sand, K.E.; Bostad, L.; Beisland, C. Obesity is associated with an improved cancer-specific survival, but an increased rate of postoperative complications after surgery for renal cell carcinoma. Scand. J. Urol. Nephrol. 2012, 46, 348–357. [Google Scholar] [CrossRef] [PubMed]
- Kupilas, A.; Fryczkowski, M. Powikłania po operacjach organooszczędzających nerki. Przegląd. Urol. 2007, 5, 31–33. [Google Scholar]
- Montag, S.; Rais-Bahrami, S.; Seideman, C.A.; Rastinehad, A.R.; Vira, M.A.; Kavoussi, L.R.; Richstone, L. Delayed haemorrhage after laparoscopic partial nephrectomy: Frequency and angiographic findings. BJU Int. 2011, 107, 1460–1466. [Google Scholar] [CrossRef]
- Campbell, S.C.; Novick, A.C.; Belldegrun, A.; Blute, M.L.; Chow, G.K.; Derweesh, I.H.; Faraday, M.M.; Kaouk, J.H.; Leveillee, R.J.; Matin, S.F.; et al. Guidelines for management of the clinical T1 renal mass. J. Urol. 2009, 182, 1271–1279. [Google Scholar] [CrossRef]
- Nadu, A.; Kleinmann, N.; Laufer, M.; Dotan, Z.; Winkler, H.; Ramon, J. Laparoscopic partial nephrectomy for central tumors: Analysis of perioperative outcomes and complications. J. Urol. 2009, 181, 42–47. [Google Scholar] [CrossRef]
- Ramani, A.P.; Desai, M.M.; Steinberg, A.P.; Ng, C.S.; Abreu, S.C.; Kaouk, J.H.; Finelli, A.; Novick, A.C.; Gill, I.S. Complications of laparoscopic partial nephrectomy in 200 cases. J. Urol. 2005, 173, 42–47. [Google Scholar] [CrossRef]
- Van Poppel, H.; Bamelis, B.; Oyen, R.; Baert, L. Partial nephrectomy for renal cell carcinoma can achieve long-term tumor control. J. Urol. 1998, 160, 674–678. [Google Scholar] [CrossRef]
- Uchida, Y.; Takazawa, R.; Kitayama, S.; Tsujii, T. Predictive risk factors for systemic inflammatory response syndrome following ureteroscopic laser lithotripsy. Urolithiasis 2018, 46, 375–381. [Google Scholar] [CrossRef]
- Martov, A.; Gravas, S.; Etemadian, M.; Unsal, A.; Barusso, G.; D’Addessi, A.; Krambeck, A.; de la Rosette, J.; on behalf of the Clinical Research Office of the Endourological Society Ureteroscopy Study Group. Postoperative infection rates in patients with a negative baseline urine culture undergoing ureteroscopic stone removal: A matched case-control analysis on antibiotic prophylaxis from the CROES URS global study. J. Endourol. 2015, 29, 171–180. [Google Scholar] [CrossRef]
- Moses, R.A.; Agarwal, D.; Raffin, E.P.; Viers, B.R.; Sharma, V.; Krambeck, A.E.; Pais, V.M. Postpercutaneous nephrolithotomy systemic inflammatory response syndrome is not associated with unplanned readmission. Urology 2017, 100, 33–37. [Google Scholar] [CrossRef]
- Akdeniz, E.; Ozturk, K.; Ulu, M.B.; Gur, M.; Caliskan, S.T.; Sehmen, E. Risk factors for systemic inflammatory response syndrome in patients with negative preoperative urine culture after percutaneous nephrolithotomy. J. Coll. Phys. Surg. Pak. 2021, 31, 410–416. [Google Scholar]
- Takenaka, K.; Ogawa, E.; Wada, H.; Hirata, T. Systemic inflammatory response syndrome and surgical stress in thoracic surgery. J. Crit. Care. 2006, 21, 48–53. [Google Scholar] [CrossRef] [PubMed]
- Haga, Y.; Beppu, T.; Doi, K.; Nozawa, F.; Mugita, N.; Ikei, S.; Ogawa, M. Systemic inflammatory response syndrome and organ dysfunction following gastrointestinal surgery. Crit. Care Med. 1997, 25, 1994–2000. [Google Scholar] [CrossRef]
- Becher, R.D.; Hoth, J.J.; Miller, P.R.; Meredith, J.W.; Chang, M.C. Systemic inflammation worsens outcomes in emergency surgical patients. J. Trauma Acute Care Surg. 2012, 72, 1140–1149. [Google Scholar] [CrossRef]
- Smajic, J.; Tupkovic, L.R.; Husic, S.; Avdagic, S.; Hodzic, S.; Imamovic, S. Systemic inflammatory response syndrome in surgical patients. Med. Arch. 2018, 72, 116–119. [Google Scholar] [CrossRef]
- Volpe, A.; Blute, M.L.; Ficarra, V.; Gill, I.S.; Kutikov, A.; Porpiglia, F.; Rogers, C.; Touijer, K.A.; Van Poppel, H.; Thompson, R.H. Renal ischemia and function after partial nephrectomy: A collaborative review of the literature. Eur. Urol. 2015, 68, 61–74. [Google Scholar] [CrossRef]
- Thompson, R.H.; Lane, B.R.; Lohse, C.M.; Leibovich, B.C.; Fergany, A.; Frank, I.; Gill, I.S.; Blute, M.L.; Campbell, S.C. Renal function after partial nephrectomy: Effect of warm ischemia relative to quantity and quality of preserved kidney. Urology 2012, 79, 356–360. [Google Scholar] [CrossRef]
Study Variable | SIRS n = 127 (44.6%) | No SIRS n = 158 (55.4%) | p |
---|---|---|---|
Sex M/F, n (%) | 67/60 (52.8/47.2) | 86/72 (54.4/45.6) | 0.78 |
Age, years | 62 (11) | 64 (12) | 0.25 |
Age ≥ 65 years, n (%) | 56 (44.1) | 84 (53.2) | 0.13 |
Comorbidities, n (%) | 68 (53.5.7) | 109 69.0) | <0.01 |
Hypertension, n (%) | 83 (65.4) | 101 (63.9) | 0.80 |
T2DM, n (%) | 34 (26.8) | 31 (19.6) | 0.15 |
BMI, kg/m2 | 27.3 (2.9) | 24.0 (3.2) | <0.001 |
Overweight, n (%) | 91 (71.7) | 71 (44.9) | |
<0.001 | |||
Obesity, n (%) | 21 (16.5) | 5 (3.3) | |
ASA > 2, n (%) | 54 (42.5) | 24 (15.2) | <0.001 |
Solitary kidney, n (%) | 2 (1.6) | 5 (3.2) | 0.47 |
Cancer local recurrence, n (%) | 5 (3.9) | 2 (3.2) | 0.15 |
Operated side: R/L, n (%) | 70/57 (55.1/44.9) | 65/93 (41.1/58.9) | <0.05 |
Tumor diameter, cm | 4.0 (2.5; 5.0) | 3.6 (2.5; 6.0) | 0.76 |
Multifocal tumor, n (%) | 12 (9.4) | 8 (5.1) | 0.17 |
TNM: T1a, n (%) | 78 (61.4) | 97 (61.4) | |
TNM: T1b, n (%) | 37 (29.1) | 46 (29.1) | |
TNM: T2a, n (%) | 7 (5.5) | 10 (6.3) | 0.95 |
TNM: T2b, n (%) | 3 (2.4) | 4 (2.5) | |
TNM: T3a, n (%) | 2 (1.6) | 1 (0.7) | |
Surgery type: NSS/nephrectomy, n (%) | 77/50 (60.6/39.4) | 78/80 (49.4/50.6) | 0.058 |
Intraoperative blood loss, mL | 180 (120; 250) | 120 (80; 190) | <0.001 |
Ischemia time, min | 12.1 (4.0) | 11.9 (3.8) | 0.71 |
Creatinine, mg/dL | 1.0 (0.8; 1.1) | 1.0 (0.9; 1.1) | 0.77 |
Creatinine > 1.1/1.4 mg/dL *, n (%) | 10 (7.9) | 16 (10.1) | 0.51 |
HR, 1/min | 85 (11) | 80 (7) | <0.001 |
Postoperative body temperature, °C | 36.4 (1.1) | 36.5 (0.7) | 0.47 |
Respiratory rate, 1/min | 18 (4) | 16 (3) | <0.001 |
Leukocytes, G/L | 14.7 (12.5; 17.0) | 11.2 (9.1; 13.6) | <0.001 |
Leukocytes > G/L, n (%) | 109 (85.8) | 98 (62.0) | <0.001 |
Hospitalization time, days | 6 (5; 7) | 5 (4; 7) | <0.05 |
Study Variable | Univariable Analysis | Multivariable Analysis | ||
---|---|---|---|---|
OR | ±95% CI | OR | 95% CI | |
Sex F vs. M | 1.070 | 0.668–1.712 | ||
Age | 0.988 | 0.968–1.008 | ||
Age ≥ 65 years | 0.695 | 0.433–1.114 | ||
Comorbidities | 0.518 ** | 0.318–0.843 | 0.359 * | 0.168–0.777 |
BMI | 1.461 # | 1.315–1.623 | ||
Obesity/overweight | 8.056 # | 4.310–15.057 | 4.998 # | 2.246–11.122 |
ASA > 2 | 4.130 # | 2.355–7.243 | 7.205 # | 3.221–16.001 |
Tumor diameter | 0.978 | 0.888–1.077 | ||
NSS vs. nepherctomy | 1.579 | 0.982–2.541 | ||
Intraoperative blood loss (per 100 mL) | 1.773 # | 1.351–2.326 | 2.471 # | 1.695–3.603 |
Ischemia time | 1.016 | 0.935–1.103 | ||
HR | 1.713 # | 1.306–2.246 | 2.143 # | 1.428–3.216 |
Respiratory rate | 3.607 # | 2.362–5.511 | 3.211 # | 1.808–5.702 |
Leukocytes > G/L | 3.707 # | 2.042–6.729 | 7.705 # | 3.221–18.428 |
Study Variable | SIRS n = 35 (12.3%) | No SIRS n = 250 (87.7%) | p |
---|---|---|---|
Sex M/F, n (%) | 25/10 (71.4/28.6) | 128/122 (51.2/48.8) | 0.06 |
Age, years | 62 (11) | 63 (12) | 0.68 |
Age ≥ 65 years, n (%) | 14 (40.0) | 126 (50.4) | 0.25 |
Comorbidities, n (%) | 19 (54.3) | 158 (63.2) | 0.31 |
Hypertension, n (%) | 21 (60.0) | 163 (65.2) | 0.55 |
T2DM, n (%) | 12 (34.3) | 53 (21.2) | 0.084 |
BMI, kg/m2 | 27.8 (2.4) | 25.1 (3.5) | <0.001 |
Overweight, n (%) | 28 (80.0) | 134 (53.6) | |
<0.001 | |||
Obesity, n (%) | 5 (14.3) | 21 (8.4) | |
ASA > 2, n (%) | 21 (60.0) | 57 (22.8) | <0.001 |
Solitary kidney, n (%) | 1 (2.9) | 6 (2.4) | 1.00 |
Cancer local recurrence, n (%) | 2 (5.7) | 5 (2.0) | 0.21 |
Operated side: R/L, n (%) | 20/15 (57.1/42.9) | 115/135 (46.0/54.0) | 0.22 |
Tumor diameter, cm | 4.0 (3.0; 6.0) | 3.5 (2.5; 5.5) | 0.11 |
Multifocal tumor, n (%) | 7 (20.0) | 13 (5.2) | <0.01 |
TNM: T1a, n (%) | 21 (60.0) | 154 (61.6) | |
TNM: T1b, n (%) | 7 (20.0) | 76 (30.4) | |
TNM: T2a, n (%) | 4 (11.4) | 13 (5.2) | 0.19 |
TNM: T2b, n (%) | 2 (5.7) | 5 (2.0) | |
TNM: T3a, n (%) | 1 (2.9) | 2 (0.8) | |
Surgery type: NSS/nephrectomy, n (%) | 16/19 (45.7/54.3) | 139/111 (55.6/44.4) | 0.27 |
Intraoperative blood loss, mL | 220 (150; 250) | 140 (100; 200) | <0.001 |
Ischemia time, min | 12.3 (4.4) | 12.0 (3.9) | 0.74 |
Creatinine, mg/dL | 1.0 (0.8; 1.2) | 1.0 (0.8; 1.1) | 0.23 |
Creatinine > 1.1/1.4 mg/dL *, n (%) | 5 (14.3) | 21 (8.4) | 0.26 |
Δ HR, % | 6.3 (16.0) | –5.7 (12.6) | <0.001 |
Δ body temperature, % | –2.1 (7.4) | 0.7 (1.9) | <0.05 |
Δ respiratory rate, % | –1.9 (23.7) | –8.7 (18.3) | 0.11 |
Δ leukocytes, % | –12.1 (–30.0; 15.4) | –26.0 (–39.3; –11.1) | <0.01 |
SIRST0, n (%) | 33 (94.3) | 94 (37.6) | <0.001 |
LeukocytesT0 > G/L, n (%) | 29 (82.9) | 178 (71.2) | 0.15 |
LeukocytesT3 > G/L, n (%) | 31 (88.6) | 79 (31.6) | <0.001 |
Hospitalization time, days | 7 (5; 8) | 6 (4; 6) | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Marcinek, M.; Tkocz, M.; Marczewski, K.; Partyka, R.; Kukulski, L.; Młynarek-Śnieżek, K.; Sędziak-Marcinek, B.; Rajwa, P.; Berezowski, A.; Kokocińska, D. Evaluation of Parameters Affecting the Occurrence of Systemic Inflammatory Response Syndrome in Patients Operated on Due to Kidney Tumors. Biomedicines 2023, 11, 2195. https://doi.org/10.3390/biomedicines11082195
Marcinek M, Tkocz M, Marczewski K, Partyka R, Kukulski L, Młynarek-Śnieżek K, Sędziak-Marcinek B, Rajwa P, Berezowski A, Kokocińska D. Evaluation of Parameters Affecting the Occurrence of Systemic Inflammatory Response Syndrome in Patients Operated on Due to Kidney Tumors. Biomedicines. 2023; 11(8):2195. https://doi.org/10.3390/biomedicines11082195
Chicago/Turabian StyleMarcinek, Mateusz, Michał Tkocz, Kamil Marczewski, Robert Partyka, Leszek Kukulski, Krystyna Młynarek-Śnieżek, Bogumiła Sędziak-Marcinek, Paweł Rajwa, Adam Berezowski, and Danuta Kokocińska. 2023. "Evaluation of Parameters Affecting the Occurrence of Systemic Inflammatory Response Syndrome in Patients Operated on Due to Kidney Tumors" Biomedicines 11, no. 8: 2195. https://doi.org/10.3390/biomedicines11082195
APA StyleMarcinek, M., Tkocz, M., Marczewski, K., Partyka, R., Kukulski, L., Młynarek-Śnieżek, K., Sędziak-Marcinek, B., Rajwa, P., Berezowski, A., & Kokocińska, D. (2023). Evaluation of Parameters Affecting the Occurrence of Systemic Inflammatory Response Syndrome in Patients Operated on Due to Kidney Tumors. Biomedicines, 11(8), 2195. https://doi.org/10.3390/biomedicines11082195